Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis First To File EU Lucentis Rival

Confirms SB11 Ranibizumab Biosimilar Candidate Accepted For Filing By EMA

Executive Summary

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.

You may also be interested in...



Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.

Samsung Biologics Sets Out Growth Plans

Samsung Biologics has set out growth plans – including for its Samsung Bioepis biosimilars venture and its CDMO business – after its sales passed the KRW1trn threshold in 2020.

Samsung Bioepis Confident Eylea And Lucentis Biosimilars Can Coexist

In an exclusive interview, Samsung Bioepis’ head of clinical research, Il Sun Hong, tells Generics Bulletin how the company managed to put itself at the head of the pack in the chase for biosimilar Eylea (aflibercept); and how the biosimilar can coexist with biosimilars to Lucentis (ranibizumab), which may debut later this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel